Legend Biotech
在场
Legend Biotech 是一家在股票代码 LEGN (US) 下上市的公司。
高管
查看带有其 31 名主要高管的组织结构图
Legend Biotech 搜索最多的简介
- Ying Huang, Director, Chief Executive Officer and Chief Financial ...
- Frank Zhang, Chairman of the Board
- Philip Yau, Director
高管在Legend Biotech变化
- Alan Bash已作为President of CARVYKTI®加入公司 (新闻发布的2024十一月5号).
- Peter Salovey已作为Director加入公司 (新闻发布的2024八月9号).
创建提醒
跟踪 Legend Biotech 的高管变动
生物技术
Legend Biotech 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
生物技术 行业的其他推荐联系人
消息
Legend Biotech 的最新新闻稿
- Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results - Legend Biotech
- Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia - Legend Biotech
- CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line - Legend Biotech
- Press Releases - Legend Biotech
- Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Legend Biotech
- Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024 – Legend BiotechBack ButtonSearch IconFilter Icon
- Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma – Legend BiotechBack ButtonSearch IconFilter Icon
- Newsroom - Legend Biotech
- Legend Biotech to Participate in the Jefferies Global Healthcare Conference – Legend BiotechBack ButtonSearch IconFilter Icon
- Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA – Legend BiotechBack ButtonSearch IconFilter Icon
- View more press releases Close
通过电子邮件
